Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer

NCT01062503 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01062503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01062503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Completed
Start date
January 31, 2010
Completion date
June 30, 2014
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastasis, metastatic prostate cancer